CytRx to Present at NYSSA 10th Annual Biotech & Specialty Pharmaceutical Conference.Webcast Scheduled December 12(th) at 9:30 a.m. ET LOS ANGELES -- CytRx Corporation (Nasdaq:CYTR CYTR Canadian Yorkshire Terrier Rescue CYTR Constant Yield Tax Rate (property tax) ) today announced that Matthew Natalizio, CytRx's Chief Financial Officer, is scheduled to present at The New York Society of Security Analysts (NYSSA Nyssa (nĭs`ə), name of several ancient cities devoted to the worship of Dionysus. The best known of them is a town of Cappadocia, Asia Minor, near the Halys (now the Kizil Irmak) River. It was the residence of St. Gregory of Nyssa. ) 10th Annual Biotech & Specialty Pharmaceutical Industry Conference on Tuesday, December 12, at 9:30 a.m. Eastern Time. The conference will be held on December 12, 2006, 8:30 a.m. to 5:10 p.m., and December 13, 2006, 8:30 a.m. to 4:30 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . A live audio webcast and slide presentation will be available under "Events Calendar" in the "News & Events" section of the Company Web site at www.cytrx.com. An archived presentation will be available for 90 days starting approximately three hours after the initial presentation. To register for this conference or for more information, please visit www.nyssa.org. NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,500 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 134 societies worldwide that make up CFA Institute, which has more than 83,000 members. About CytRx Corporation CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone chaperone /chap·er·one/ (shap´er-on) someone or something that accompanies and oversees another. molecular chaperone " co-induction technology. In September 2006, CytRx announced receipt of $24.5 million in a non-dilutive agreement with the privately-funded ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. Charitable Remainder Trust charitable remainder trust (Charitable Remainder Irrevocable Unitrust) n. a form of trust in which the donor (trustor or settlor) places substantial funds or assets into an irrevocable trust (a trust in which the basic terms cannot be changed or the gift withdrawn) to fund continued arimoclomol development for the treatment for ALS in return for a one percent royalty from potential worldwide sales of arimoclomol for the treatment of ALS. The Greater Los Angeles Chapter of The ALS Association is the charitable beneficiary of the ALS Charitable Remainder Trust. CytRx has a broad-based strategic alliance with the University of Massachusetts Medical School UMMS is ranked fourth in primary care education among the nation’s 125 medical schools in the 2006 U.S.News & World Report annual guide, “America’s Best Graduate Schools”. UMMS is also a major center for research. to develop novel compounds in the areas of ALS, obesity, type 2 diabetes type 2 diabetes n. See diabetes mellitus. and cytomegalovirus cytomegalovirus (sī'təmĕg'əlōvī`rəs), member of the herpesvirus family that can cause serious complications in persons with weakened immune systems. (CMV) using RNAi technology. The Company has a research program with Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world , Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. CytRx's Drug Discovery division, located in Worcester, Massachusetts, focuses on the use of RNAi technologies to develop small molecule and RNAi therapeutics to treat obesity and type 2 diabetes. For more information, visit CytRx's Web site at www.cytrx.com. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion